- Home
- BTU vs CELC Comparison
BTU vs CELC Comparison
Compare BTU & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTU
- CELC
- Stock Information
- Founded
- BTU 2016
- CELC 2011
- Country
- BTU United States
- CELC United States
- Employees
- BTU N/A
- CELC N/A
- Industry
- BTU Coal Mining
- CELC Medical Specialities
- Sector
- BTU Energy
- CELC Health Care
- Exchange
- BTU Nasdaq
- CELC Nasdaq
- Market Cap
- BTU 3.5B
- CELC 3.1B
- IPO Year
- BTU N/A
- CELC 2017
- Fundamental
- Price
- BTU $28.69
- CELC $92.18
- Analyst Decision
- BTU Strong Buy
- CELC Strong Buy
- Analyst Count
- BTU 7
- CELC 6
- Target Price
- BTU $26.43
- CELC $90.00
- AVG Volume (30 Days)
- BTU 4.0M
- CELC 1.3M
- Earning Date
- BTU 10-30-2025
- CELC 11-12-2025
- Dividend Yield
- BTU 1.04%
- CELC N/A
- EPS Growth
- BTU N/A
- CELC N/A
- EPS
- BTU N/A
- CELC N/A
- Revenue
- BTU $3,962,300,000.00
- CELC N/A
- Revenue This Year
- BTU N/A
- CELC N/A
- Revenue Next Year
- BTU $17.31
- CELC N/A
- P/E Ratio
- BTU N/A
- CELC N/A
- Revenue Growth
- BTU N/A
- CELC N/A
- 52 Week Low
- BTU $9.61
- CELC $7.58
- 52 Week High
- BTU $35.99
- CELC $94.06
- Technical
- Relative Strength Index (RSI)
- BTU 49.58
- CELC 78.54
- Support Level
- BTU $28.68
- CELC $72.05
- Resistance Level
- BTU $31.03
- CELC $75.02
- Average True Range (ATR)
- BTU 1.62
- CELC 4.49
- MACD
- BTU -0.17
- CELC 0.92
- Stochastic Oscillator
- BTU 62.99
- CELC 91.48
About BTU Peabody Energy Corporation
Peabody Energy Corp is a producer of metallurgical and thermal coal. It also markets and brokers coal, both as principal and agent, and trades coal and freight-related contracts. The company operates in the following segment: Seaborne Thermal, Seaborne Metallurgical, Powder River Basin, Other U.S. Thermal and Corporate and Other. The Seaborne Thermal segment generates the majority of the revenue for the company. A substantial part of its overall revenue is generated from its customers in the United States, and rest from Japan, China, Australia, Taiwan and other regions.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.